Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other financing activities (2018 - 2021)

ImmunityBio (IBRX) has disclosed Other financing activities for 3 consecutive years, with -$1.2 million as the latest value for Q3 2021.

  • On a quarterly basis, Other financing activities fell 629.45% to -$1.2 million in Q3 2021 year-over-year; TTM through Dec 2022 was -$1.2 million, a 182.86% decrease, with the full-year FY2021 number at $1.4 million, changed N/A from a year prior.
  • Other financing activities was -$1.2 million for Q3 2021 at ImmunityBio, down from $2.6 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.6 million in Q1 2021 to a low of -$1.2 million in Q3 2021.
  • A 3-year average of $201285.7 and a median of $40000.0 in 2019 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 2033.33% in 2021; the steepest drop was 629.45% in 2021.
  • ImmunityBio's Other financing activities stood at -$66000.0 in 2019, then plummeted by 146.97% to -$163000.0 in 2020, then plummeted by 629.45% to -$1.2 million in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Other financing activities are -$1.2 million (Q3 2021), $2.6 million (Q1 2021), and -$163000.0 (Q3 2020).